**Novocure Announces the Presentation of New Data at the 19th Annual Society of Neuro-Oncology Meeting**

*Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation.*

Data from ten clinical and preclinical abstracts on Tumor Treating Fields from leading academic institutions will also be presented at the meeting.

**St. Helier, Jersey – November 11, 2014** – Novocure™, a commercial stage oncology company, announced today that the pre-specified interim analysis of the pivotal phase III EF-14 study, a prospective, multi-center trial of Tumor Treating Fields (TTFields) together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM), will be presented as a late breaking oral presentation at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16, in Miami, Florida. In addition to the EF-14 interim analysis presentation, an additional 10 preclinical and clinical abstracts from leading academic institutions describing the latest aspects of TTFields therapy will be presented at the meeting.

Details of the late breaking abstract oral presentation are as follows:

**Date:** Saturday, November 15, 2014  
**Venue:** Session 5B: Clinical Trials - Late Breaking Abstracts  
**Time:** 11:40 - 12:00pm EST  
**Type:** Oral Presentation

**Interim Analysis of EF-14; Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)**  
**Presenter:** Roger Stupp MD, Director, University Hospital Cancer Center, University of Zurich, Zurich, Switzerland

Details on the poster presentations are as follows:

**Alternating Electric Fields Perturb the Localization of Cytokinetic Furrow Proteins and Cause Aberrant Mitotic Exit**  
**Presenter:** Yang et al  
**Abstract Number:** ET-68  
**Time:** Poster session on Friday, November 14, 2014 7:30-9:30pm ET

**Dexamethasone Interference with Alternating Electric Fields (TTFields) Therapy for Recurrent Glioblastoma**  
**Presenter:** Eric T. Wong MD, Beth Israel Deaconess Medical Center, Boston, MA  
**Abstract Number:** AT-61  
**Time:** Poster session on Friday, November 14, 2014 7:30-9:30pm ET

**Trifluoropromazine Enhances TTFields Treatment *in vitro***  
**Presenter:** Moshe Giladi PhD, Novocure Ltd. Haifa, Israel  
**Abstract Number:** ET-47  
**Time:** Poster session on Friday, November 14, 2014 7:30-9:30pm ET
An Updated Analysis of Patient Registry Data on NovoTTF-100A Alternating Electric Fields Therapy for Recurrent Glioblastoma  
**Presenter:** Eric T. Wong MD, Beth Israel Deaconess Medical Center, Boston, MA  
**Abstract Number:** ED-38  
**Time:** Poster session on Saturday, November 15, 2014 5:00-7:00pm ET

Early Japanese Experience with NovoTTF-100A System for Recurrent GBM  
**Presenter:** Nita et al  
**Abstract Number:** NT-25  
**Time:** Poster session on Saturday, November 15, 2014 5:00-7:00pm ET

Case of Glioblastoma Patient Treated with NovoTTF Therapy at Recurrence Degenerating to Sarcoma  
**Presenter:** Majd et al  
**Abstract Number:** RM-05  
**Time:** ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

EF-21: A phase II Randomized Study of TTFields Therapy Versus Supportive Care in Non-small Cell Lung Cancer (NSCLC) Patients with 1-5 Brain Metastases (BM) following Stereotactic Radio-surgery (SRS)  
**Presenter:** Uri Weinberg MD, Novocure Ltd, Haifa, Israel  
**Abstract Number:** NT-37  
**Time:** ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Investigating the Mechanisms of Action of Tumor Treating Fields: A Computational Modeling Study  
**Presenter:** Wenger et al  
**Abstract Number:** TM-16  
**Time:** ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Malignant Glioma with Primitive Neuroectodermal Components: Clinical and Pathologic Features of Five Cases  
**Presenter:** Turner et al  
**Abstract Number:** CB-16  
**Time:** ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

Pathology of Cases of Imaging Progression in Patients Diagnosed with Glioblastoma who have been Treated with the Novocure-TTF Device in the EF-14 trial  
**Presenter:** New et al  
**Abstract Number:** NT-26  
**Time:** ePoster presentation available at kiosks or online at www.soc-neuro-onc.org

About Glioblastoma  
Glioblastoma is the most common form of primary brain cancer with approximately 10,000 patients diagnosed each year in the United States. Expected overall survival from initial diagnosis is reported to be approximately 15 months. The disease is known as recurrent glioblastoma when the tumor progresses or recurs after initial treatment. Overall survival from the time of recurrence has been reported at 3-5 months without active treatment.

About the NovoTTF-100A System  
The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use by patients. *In vitro* and *in vivo* studies have shown that the NovoTTF-100A System slows and reverses tumor growth by inhibiting mitosis, the process by
which cells divide and replicate. The NovoTTF-100A System creates a low intensity, alternating electric field within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. In patients with recurrent glioblastoma brain tumors, the system has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF-100A System has received marketing approval in the United States (U.S.) under the brand name Optune™ and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel.

**Approved Indication**
The U.S. Food and Drug Administration (FDA) has approved Optune for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at [www.novottftherapy.com/safety](http://www.novottftherapy.com/safety) or by calling toll free 1-855-281-9301.

**About Novocure**
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure U.S. operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit [www.novocure.com](http://www.novocure.com).

###

**Media and Investor Contact:**
Ashley Cordova, Novocure
acordova@novocure.com
(212) 767-7558